Form 8-K - Current report:
SEC Accession No. 0001193125-22-143631
Filing Date
2022-05-06
Accepted
2022-05-06 16:06:58
Documents
12
Period of Report
2022-05-02
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d340258d8k.htm   iXBRL 8-K 22088
  Complete submission text file 0001193125-22-143631.txt   146749

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA sbtx-20220502.xsd EX-101.SCH 2860
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE sbtx-20220502_lab.xml EX-101.LAB 18738
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sbtx-20220502_pre.xml EX-101.PRE 11710
6 EXTRACTED XBRL INSTANCE DOCUMENT d340258d8k_htm.xml XML 3474
Mailing Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109
Business Address 500 FAIRVIEW AVENUE NORTH, SUITE 600 SEATTLE WA 98109 206-456-2900
Silverback Therapeutics, Inc. (Filer) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39756 | Film No.: 22901064
SIC: 2834 Pharmaceutical Preparations